Summary
This 10-Q filing for Alnylam Pharmaceuticals, Inc. covers the quarterly period ended June 30, 2005. As a clinical-stage biopharmaceutical company, Alnylam's financial performance is largely driven by its research and development activities, with significant operating losses typical for companies at this stage. Investors should focus on the company's cash burn, its progress in developing its RNA interference (RNAi) therapeutics pipeline, and its strategic partnerships and collaborations, which are crucial for funding and advancing its drug candidates. The filing indicates that the company is not an accelerated filer, suggesting it is still in an earlier stage of development and reporting maturity.
Key Highlights
- 1Alnylam Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics.
- 2The filing covers the quarterly period ended June 30, 2005, and provides unaudited interim consolidated financial statements.
- 3The company reported operating losses, which is expected for a company investing heavily in research and development.
- 4Key financial statements include Consolidated Balance Sheets, Statements of Operations and Comprehensive Loss, and Statements of Cash Flows.
- 5Management's Discussion and Analysis (MD&A) provides insights into the company's financial condition, results of operations, and outlook.
- 6The filing indicates that Alnylam was not an accelerated filer as of August 1, 2005, suggesting it is a smaller reporting company.
- 7As of August 1, 2005, there were 21,200,676 shares of Common Stock outstanding.
Frequently Asked Questions
Alnylam Pharmaceuticals is focused on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi).
As of June 30, 2005, Alnylam is a clinical-stage company and would typically be incurring significant operating expenses related to research and development, leading to net losses. Detailed financial statements (Balance Sheets, Statements of Operations, and Cash Flows) for the period are included in the filing.
Alnylam is not an accelerated filer because it does not meet the criteria for accelerated filer status, which generally applies to larger companies with a significant public float and a history of timely filings. This indicates that Alnylam is likely in an earlier stage of its development and financial reporting cycle.
The MD&A section provides management's perspective on the company's financial condition, the reasons for changes in financial results, and the company's future outlook. Investors can find insights into liquidity, capital resources, and known trends or uncertainties that may affect future performance.